Recent ABBV News
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection • PR Newswire (US) • 05/22/2026 12:00:00 PM
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline • PR Newswire (US) • 05/21/2026 10:46:00 PM
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults • PR Newswire (US) • 05/21/2026 08:10:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 09:01:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/12/2026 09:00:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/12/2026 09:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/12/2026 09:00:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 04:28:48 PM
- AbbVie to Present at the Bank of America Securities Healthcare Conference • PR Newswire (US) • 05/06/2026 12:00:00 PM
- AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week® • PR Newswire (US) • 05/05/2026 12:05:00 PM
- SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis • PR Newswire (Canada) • 05/04/2026 11:01:00 AM
- SKYRIZI® (risankizumab) est inscrit aux listes des médicaments remboursés de l'Ontario et de l'Alberta pour le traitement de la colite ulcéreuse • PR Newswire (Canada) • 05/04/2026 11:01:00 AM
- AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec • GlobeNewswire Inc. • 04/30/2026 07:00:00 PM
- Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month • PR Newswire (US) • 04/30/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:50:28 AM
- AbbVie Reports First-Quarter 2026 Financial Results • PR Newswire (US) • 04/29/2026 11:47:00 AM
- Markets Steady Ahead of Fed Decision and Key Tech Earnings: Dow Jones, S&P, Nasdaq, Wall Street Futures • IH Market News • 04/29/2026 09:16:13 AM
- Markets Hold Steady Ahead of Fed Call and Big Tech Earnings: Dow Jones, S&P, Nasdaq, Wall Street Futures • UK Market News • 04/29/2026 09:15:43 AM
- AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata • PR Newswire (US) • 04/28/2026 12:00:00 PM
- RINVOQ® (upadacitinib) s'est révélé supérieur à HUMIRA® (adalimumab) pour ce qui est du principal paramètre d'évaluation d'une étude comparative directe menée chez des patients atteints de polyarthrite rhumatoïde dont le premier traitement par • PR Newswire (Canada) • 04/28/2026 11:01:00 AM
- RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor • PR Newswire (Canada) • 04/28/2026 11:01:00 AM

